Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor
ObjectivesThis study aimed to evaluate the efficacy of low-dose interleukin (IL-2) treatment for bullous pemphigoid (BP) caused by anti-programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitors.MethodsLow-dose IL-2 treatment was standardized for BP. The Bullous Pemphigoid Disease Area Index (...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1496413/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850107921306746880 |
|---|---|
| author | Yingyue Zhang Yingyue Zhang Xianwei Cao Xianwei Cao Jianbo Tong Jianbo Tong |
| author_facet | Yingyue Zhang Yingyue Zhang Xianwei Cao Xianwei Cao Jianbo Tong Jianbo Tong |
| author_sort | Yingyue Zhang |
| collection | DOAJ |
| description | ObjectivesThis study aimed to evaluate the efficacy of low-dose interleukin (IL-2) treatment for bullous pemphigoid (BP) caused by anti-programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitors.MethodsLow-dose IL-2 treatment was standardized for BP. The Bullous Pemphigoid Disease Area Index (BPDAI), 5D-Itch Scale (5D-IS), and Dermatology Life Quality Index (DLQI) were recorded before and after treatment, and hexachromatic lymphocytes, regulatory T cells (Treg cells), and cytokines were measured.ResultsA significant decline in the BPDAI score, 5D-IS, and DLQI score was observed following treatment. The count of B-cells, CD4+ T-cells, CD8+ T-cells, Treg cells, and the levels of cytokines (IL-4, -8, and -10) were significantly downregulated in comparison to baseline measurements.ConclusionLow-dose IL-2 could be an effective therapeutic choice for treating BP caused by PD-1/PD-L1 inhibitors. |
| format | Article |
| id | doaj-art-50a5dad4aee9438e8e80eb8bc281aed2 |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-50a5dad4aee9438e8e80eb8bc281aed22025-08-20T02:38:29ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-12-011510.3389/fimmu.2024.14964131496413Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitorYingyue Zhang0Yingyue Zhang1Xianwei Cao2Xianwei Cao3Jianbo Tong4Jianbo Tong5Department of Dermatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, ChinaInstitute of Dermatology, Jiangxi Academy of Clinical Medical Sciences, Nanchang, ChinaDepartment of Dermatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, ChinaInstitute of Dermatology, Jiangxi Academy of Clinical Medical Sciences, Nanchang, ChinaDepartment of Dermatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, ChinaInstitute of Dermatology, Jiangxi Academy of Clinical Medical Sciences, Nanchang, ChinaObjectivesThis study aimed to evaluate the efficacy of low-dose interleukin (IL-2) treatment for bullous pemphigoid (BP) caused by anti-programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitors.MethodsLow-dose IL-2 treatment was standardized for BP. The Bullous Pemphigoid Disease Area Index (BPDAI), 5D-Itch Scale (5D-IS), and Dermatology Life Quality Index (DLQI) were recorded before and after treatment, and hexachromatic lymphocytes, regulatory T cells (Treg cells), and cytokines were measured.ResultsA significant decline in the BPDAI score, 5D-IS, and DLQI score was observed following treatment. The count of B-cells, CD4+ T-cells, CD8+ T-cells, Treg cells, and the levels of cytokines (IL-4, -8, and -10) were significantly downregulated in comparison to baseline measurements.ConclusionLow-dose IL-2 could be an effective therapeutic choice for treating BP caused by PD-1/PD-L1 inhibitors.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1496413/fullbullous pemphigoidLow-dose IL-2PD-1/PD-L1 inhibitorperifollicular blisteringimmunotherapy |
| spellingShingle | Yingyue Zhang Yingyue Zhang Xianwei Cao Xianwei Cao Jianbo Tong Jianbo Tong Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor Frontiers in Immunology bullous pemphigoid Low-dose IL-2 PD-1/PD-L1 inhibitor perifollicular blistering immunotherapy |
| title | Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor |
| title_full | Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor |
| title_fullStr | Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor |
| title_full_unstemmed | Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor |
| title_short | Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor |
| title_sort | case report low dose interleukin 2 a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by pd 1 pd l1 inhibitor |
| topic | bullous pemphigoid Low-dose IL-2 PD-1/PD-L1 inhibitor perifollicular blistering immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1496413/full |
| work_keys_str_mv | AT yingyuezhang casereportlowdoseinterleukin2atreatmentofbullouspemphigoidwithpredominantlyperifollicularblisteringcausedbypd1pdl1inhibitor AT yingyuezhang casereportlowdoseinterleukin2atreatmentofbullouspemphigoidwithpredominantlyperifollicularblisteringcausedbypd1pdl1inhibitor AT xianweicao casereportlowdoseinterleukin2atreatmentofbullouspemphigoidwithpredominantlyperifollicularblisteringcausedbypd1pdl1inhibitor AT xianweicao casereportlowdoseinterleukin2atreatmentofbullouspemphigoidwithpredominantlyperifollicularblisteringcausedbypd1pdl1inhibitor AT jianbotong casereportlowdoseinterleukin2atreatmentofbullouspemphigoidwithpredominantlyperifollicularblisteringcausedbypd1pdl1inhibitor AT jianbotong casereportlowdoseinterleukin2atreatmentofbullouspemphigoidwithpredominantlyperifollicularblisteringcausedbypd1pdl1inhibitor |